Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F18%3A43914521" target="_blank" >RIV/62156489:43210/18:43914521 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00104807 RIV/00216305:26620/18:PU130367 RIV/65269705:_____/18:00069248
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/10.1002/cam4.1767" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/cam4.1767</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/cam4.1767" target="_blank" >10.1002/cam4.1767</a>
Alternative languages
Result language
angličtina
Original language name
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
Original language description
To date, there has been no evidence regarding the association between urinary sarcosine content and prostate cancer survival. Our main objective was to investigate whether levels of post-treatment urinary sarcosine are associated with relapse. The inclusion criteria were (in accordance with EAU 2017) as follows: histopathologically verified adenocarcinoma in prostate biopsy cores or specimens from transurethral resection of the prostate (TURP) or prostatectomy for benign prostatic enlargement (BPE) with retained ability to urinate. The median follow-up was 53 months. In the study, we retrospectively evaluated a cohort of 511 patients with prostate cancer with various risk factors and treatment strategies. Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (>= 200 nmol/L) in 71 (13%) patients. Urinary sarcosine content was significantly associated with number of relapses that patients experienced, P = 0.002 for sarcosine >= 200 vs <= 30 nmol/L. Multivariate analysis revealed that sarcosine was an independent predictor of recurrent relapses (>= 2 relapses with an intermediate period of remission), HR = 3.89 (95% CI 1.29-11.7) for sarcosine >200 vs <30 nmol/L. This trend was even more pronounced in a subgroup of patients who underwent radical prostatectomy, HR = 3.29 (95% CI 1.06-10.18), where (single) relapse-free survival could also be predicted by sarcosine levels, HR = 1.96 (1.05-3.66). Urinary sarcosine may become a possible predictor for patients' outcomes, because patients with elevated post-treatment sarcosine could be predicted to have recurrent relapses of the disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Medicine
ISSN
2045-7634
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
5411-5419
UT code for WoS article
000450673300009
EID of the result in the Scopus database
2-s2.0-85053412183